BLUEHOLE-NEW-CONSUMPTION
12.5.2022 11:49:09 CEST | Business Wire | Press release
China’s leading vaping media, Bluehole New Consumption, today publishes an industry comment on Vuse overtaking Juul and becoming the U.S vaping market champion again.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220512005478/en/
Here below is the full article:
According to Nielsen, for the two weeks ended April 9, 2022, Vuse has surpassed Juul and become No.1 in U.S. e-cigarette sales with a market share of 35 percent, driven by the sale of its flagship product Vuse Alto, which represented over 90% of Vuse revenues in the U.S. in 2021. Being back on top in the U.S market has strengthened Vuse's global leadership.
It is another milestone for Vuse to be the U.S top-selling vaping brand again, since Juul overtook it in 2017. Juul, the emerging brand founded in 2015, had already captured a massive 68% share of the US vaping market within 3 years while Vuse's market share had reduced to 10% from 44.2% in 2016.
In order to turn the tide in the competition against Juul, Vuse had started searching for a new manufacturer and atomization technology provider on a global scale, and considered introducing a game-changing product. In 2018, Vuse entered into partnership with FEELM, the flagship atomization tech brand belonging to SMOORE and soon launched Vuse Alto in August.
In contract to Juul, which mounts traditional cotton coil, Vuse Alto provides a revolutionary vaping experience by adopting FEELM ceramic coil, and Vuse also started swinging momentum in its favor. Since 2019, Vuse's US market share has rocketed, with Vuse Alto becoming one of the most popular vaping products worldwide. In 2021, Vuse announced to be No.1 global vaping brand and reached a full year value share of 33.5% in the top five vapor markets (the U.S, Canada, France, Germany and the UK), which account for approximately 75% of total industry vapor revenue (closed-system). In the US market, Vuse’s US value share reached 35.9% in December 2021. It has managed to close 27% value share point gap in just 2 years, with only 0.1% difference with Juul (36%).
Equipped with an industry-leading ceramic coil, Vuse Alto brings a consistently smooth vaping experience and boasts a long-lasting pod with extraordinary leakage-proof performance. Moreover, due to the authentic flavor reproduction of FEELM ceramic coil, Vuse Alto features a full-bodied, rich taste of tobacco and menthol. It becomes an increasingly prominent competitive edge, especially after the U.S FDA banned e-cigarettes with flavors other than tobacco and menthol in February 2020, to address youth vaping epidemic. Meanwhile, Juul has been stuck in youth marketing controversy and faced mounting state lawsuits in the US.
In October 2021, the FDA has issued first marketing granted orders to Vuse (Solo), recognizing the public health benefits of Vuse products, particularly for addicted adult smokers seeking for switchover. Later in April 2022, the FDA has approved NJOY Ace for sale. This latest approved product is also powered by FEELM atomization technology, thereby reaffirming the harm reduction potential of this ceramic coil. Moreover, Vuse Alto shares the same FEELM atomization technology with NJOY Ace.
To read the original article, please visit: https://bluehole.com.cn/news/detail/49834
View source version on businesswire.com: https://www.businesswire.com/news/home/20220512005478/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Great Britain Leads Europe’s FMCG Inflation as NIQ Launches New Inflation Barometer6.8.2026 09:00:00 CEST | Press release
NIQ (NYSE: NIQ) today launches its new EU5 FMCG Inflation Barometer - a monthly tracker across five Western Europe markets – France, Great Britain, Germany, Italy and Spain – designed to help retailers, manufacturers and the media understand how inflation is evolving across Europe’s largest grocery markets and how shoppers are responding. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806579111/en/ EU5 CPG Inflation slows to +1.1% The first edition of the Barometer reveals that while inflation across Europe’s FMCG sector remains relatively contained overall, significant differences persist between countries. Key findings include: Great Britain recorded the highest FMCG inflation across the EU5 at +2.3%1, above the European average of +1.1%. France and Italy reported the lowest inflation at -0.4% and +0.6% retrospectively, highlighting the uneven inflationary landscape across Europe's major economies. The monthly Barometer
NTT DOCOMO BUSINESS and Chile’s State-owned Copper Company CODELCO Launch a Study and Proof of Concept Aimed at Improving the Efficiency of Remote Copper Mine Operations Using IOWN® APN6.8.2026 06:30:00 CEST | Press release
NTT DOCOMO BUSINESS, Inc. (formerly NTT Communications Corporation) has launched a study and proof of concept jointly with Corporación Nacional del Cobre de Chile (CODELCO) to progress remote operations at CODELCO’s copper mines using an IOWN® All-Photonics Network (APN).1 This initiative is part of a research project commissioned by Japan’s Ministry of Internal Affairs and Communications.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806845222/en/ Conceptual Diagram of the Demonstration To address operational challenges faced by CODELCO’s copper mines, the initiative will connect a copper mine and a remote operations center—approximately 1,500 km apart—via an IOWN APN. It will assess the feasibility of remotely operating heavy machinery using high-capacity, low-latency communication links, enhancing monitoring operations through high-definition video, and implementing a remote operations model. 1. Background Chile is o
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
